YARW — YARROW BIOSCIENCE Share News
0.000.00%
Last trade - 00:00- $181.86m
- $158.94m
- $0.57m
Vyne Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
Brief: Vyne Therapeutics Inc Files For Mixed Shelf Offering Of Upto $250 Million- SEC Filing
Brief: VYNE Therapeutics FY Adjusted Net Income USD -25.147 Million
Brief: VYNE Therapeutics Q3 Adjusted Net Income USD -5.721 Million
U.S. STOCKS ON THE MOVE-SeaStar, SJW Group, Pinterest
U.S. STOCKS ON THE MOVE-Crypto, Miromatrix Medical, US banks
U.S. STOCKS ON THE MOVE-JinkoSolar, Reviva, MeiraGTx
VYNE Therapeutics jumps on positive trial data, funding plan
Brief: Vyne Therapeutics Reports Positive Results From Preclinical Models For Oral BD2-Selective BET Inhibitor VYN202
Brief: Vyne Therapeutics Announces Positive Data From Phase 1B Trial For Novel Bet Inhibitor Vyn201 In Patients With Nonsegmental Vitiligo
Brief: VYNE Therapeutics Inc. Q2 Basic EPS USD -3.09
Vyne Therapeutics Inc expected to post a loss of $1.99 a share - Earnings Preview
Vyne Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Vyne Therapeutics Reports First Quarter 2023 Financial Results
Vyne Therapeutics Inc expected to post a loss of $2.61 a share - Earnings Preview
Brief: Vyne Therapeutics Announces Selection Of Development Candidate Vyn202, A Potential Best-In-Class Oral Small Molecule Bd2-Selective Bet Inhibitor For Treatment Of Immuno-Inflammatory Conditions
U.S. STOCKS ON THE MOVE-CDW Corp, Bed Bath & Beyond, Elevance Health
U.S. STOCKS ON THE MOVE-United Airlines, Abbott Labs, Shift4 Payments
VYNE Therapeutics surges on positive lung drug data in animal study